IDEXX Laboratories, Inc.

Symbol: IDXX

NASDAQ

500.82

USD

Market price today

  • 48.0241

    P/E Ratio

  • 3.4962

    PEG Ratio

  • 41.36B

    MRK Cap

  • 0.00%

    DIV Yield

IDEXX Laboratories, Inc. (IDXX) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.60%

Operating Profit Margin

0.30%

Net Profit Margin

0.23%

Return on Assets

0.26%

Return on Equity

0.64%

Return on Capital Employed

0.47%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO:Mr. Jonathan J. Mazelsky
Full-time employees:11000
City:Westbrook
Address:One IDEXX Drive
IPO:1991-06-21
CIK:0000874716

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

General Outlook

When we look at how much money they make before expenses, they keep 0.601% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.300%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.233%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.258% return, is a testament to IDEXX Laboratories, Inc.'s adeptness in optimizing resource deployment. IDEXX Laboratories, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.637%. Furthermore, the proficiency of IDEXX Laboratories, Inc. in capital utilization is underscored by a remarkable 0.466% return on capital employed.

Stock Prices

IDEXX Laboratories, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $485, while its low point bottomed out at $462. This variance in figures offers investors a lucid insight into the roller-coaster ride that is IDEXX Laboratories, Inc.'s stock market.

Liquidity Ratios

Analyzing IDXX liquidity ratios reveals its financial health of the firm. The current ratio of 156.96% gauges short-term asset coverage for liabilities. The quick ratio (101.96%) assesses immediate liquidity, while the cash ratio (41.53%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio156.96%
Quick Ratio101.96%
Cash Ratio41.53%

Profitability Ratios

IDXX profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 29.24% underscores its earnings before tax deductions. The effective tax rate stands at 20.42%, revealing its tax efficiency. The net income per EBT, 79.58%, and the EBT per EBIT, 97.61%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 29.95%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin29.24%
Effective Tax Rate20.42%
Net Income per EBT79.58%
EBT per EBIT97.61%
EBIT per Revenue29.95%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.57, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding102
Days of Inventory Outstanding96
Operating Cycle152.68
Days of Payables Outstanding29
Cash Conversion Cycle124
Receivables Turnover6.44
Payables Turnover12.64
Inventory Turnover3.80
Fixed Asset Turnover4.50
Asset Turnover1.11

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 11.09, and free cash flow per share, 9.59, depict cash generation on a per-share basis. The cash per share value, 4.78, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.25, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share11.09
Free Cash Flow per Share9.59
Cash per Share4.78
Operating Cash Flow Sales Ratio0.25
Free Cash Flow to Operating Cash Flow Ratio0.86
Cash Flow Coverage Ratio0.86
Short Term Coverage Ratio2.68
Capital Expenditure Coverage Ratio7.41
Dividend Paid and Capex Coverage Ratio7.41

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 31.88%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.68, we discern the balance between debt and equity financing. The long-term debt to capitalization, 31.60%, and total debt to capitalization, 40.52%, ratios shed light on its capital structure. An interest coverage of 218.76 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio31.88%
Debt Equity Ratio0.68
Long Term Debt to Capitalization31.60%
Total Debt to Capitalization40.52%
Interest Coverage218.76
Cash Flow to Debt Ratio0.86
Company Equity Multiplier2.14

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 44.07, provides a glimpse into top-line earnings distributed across each share. Net income per share, 10.17, reflects the portion of profit attributed to each share. The book value per share, 17.87, represents the net asset value distributed per share, while the tangible book value per share, 12.45, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share44.07
Net Income Per Share10.17
Book Value Per Share17.87
Tangible Book Value Per Share12.45
Shareholders Equity Per Share17.87
Interest Debt Per Share10.98
Capex Per Share-1.61

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 8.72%, indicates top-line expansion, while the gross profit growth, 9.26%, reveals profitability trends. EBIT growth, 22.07%, and operating income growth, 22.07%, offer insights into operational profitability progression. The net income growth, 24.44%, showcases bottom-line expansion, and the EPS growth, 25.25%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth8.72%
Gross Profit Growth9.26%
EBIT Growth22.07%
Operating Income Growth22.07%
Net Income Growth24.44%
EPS Growth25.25%
EPS Diluted Growth25.28%
Weighted Average Shares Growth-0.67%
Weighted Average Shares Diluted Growth-0.74%
Operating Cash Flow Growth66.95%
Free Cash Flow Growth96.09%
10-Year Revenue Growth per Share240.27%
5-Year Revenue Growth per Share72.97%
3-Year Revenue Growth per Share38.96%
10-Year Operating CF Growth per Share371.66%
5-Year Operating CF Growth per Share136.94%
3-Year Operating CF Growth per Share43.71%
10-Year Net Income Growth per Share475.93%
5-Year Net Income Growth per Share134.38%
3-Year Net Income Growth per Share49.23%
10-Year Shareholders Equity Growth per Share266.68%
5-Year Shareholders Equity Growth per Share16418.79%
3-Year Shareholders Equity Growth per Share141.30%
Receivables Growth14.18%
Inventory Growth3.39%
Asset Growth18.68%
Book Value per Share Growth145.51%
Debt Growth-29.70%
R&D Expense Growth-25.06%
SGA Expenses Growth6.01%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 46,599,731,300, captures the company's total value, considering both debt and equity. Income quality, 1.07, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.09, gauges operational efficiency, while the research and development to revenue, 5.22%, highlights investment in innovation. The ratio of intangibles to total assets, 13.82%, indicates the value of non-physical assets, and capex to operating cash flow, -14.74%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value46,599,731,300
Income Quality1.07
Sales General and Administrative to Revenue0.09
Research and Development to Revenue5.22%
Intangibles to Total Assets13.82%
Capex to Operating Cash Flow-14.74%
Capex to Revenue-3.65%
Capex to Depreciation-116.29%
Stock-Based Compensation to Revenue1.63%
Graham Number63.96
Return on Tangible Assets30.08%
Graham Net Net-9.49
Working Capital543,707,000
Tangible Asset Value1,034,069,000
Net Current Asset Value-280,141,000
Invested Capital1
Average Receivables429,032,000
Average Payables110,432,000
Average Inventory374,052,500
Days Sales Outstanding46
Days Payables Outstanding27
Days of Inventory On Hand94
ROIC35.92%
ROE0.57%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 26.53, and the price to book ratio, 26.53, reflect the market's valuation relative to the company's book value. The price to sales ratio, 11.10, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 51.91, and price to operating cash flows, 45.18, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio26.53
Price to Book Ratio26.53
Price to Sales Ratio11.10
Price Cash Flow Ratio45.18
Price Earnings to Growth Ratio3.50
Enterprise Value Multiple35.38
Price Fair Value26.53
Price to Operating Cash Flow Ratio45.18
Price to Free Cash Flows Ratio51.91
Price to Tangible Book Ratio31.06
Enterprise Value to Sales12.73
Enterprise Value Over EBITDA42.47
EV to Operating Cash Flow51.41
Earnings Yield1.83%
Free Cash Flow Yield1.68%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of IDEXX Laboratories, Inc. (IDXX) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 48.024 in 2024.

What is the ticker symbol of IDEXX Laboratories, Inc. stock?

The ticker symbol of IDEXX Laboratories, Inc. stock is IDXX.

What is company IPO date?

IPO date of IDEXX Laboratories, Inc. is 1991-06-21.

What is company current share price?

Current share price is 500.820 USD.

What is stock market cap today?

The market cap of stock today is 41361371586.000.

What is PEG ratio in 2024?

The current 3.496 is 3.496 in 2024.

What is the number of employees in 2024?

In 2024 the company has 11000.